Charles River Laboratories International, Inc. (CRL) is a global provider of non-clinical drug development and research services that support pharmaceutical, biotechnology, and academic institutions in the discovery, development, and manufacture of new therapies. Based in Wilmington, Massachusetts, the company plays a key role in the early stages of the drug development process.
Companies worth between $2 billion and $10 billion are typically classified as “mid-cap stocks,” and CRL fits the label perfectly, with its market cap of $8.9 billion, underscoring its size, influence, and dominance within the diagnostics & research industry.
